Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies
- PMID: 23460056
- DOI: 10.7326/0003-4819-158-5-201303050-00005
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies
Abstract
Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC). In the United States, this form of cancer occurs in approximately 15 000 persons annually. A systematic review of the evidence is needed to assess the benefits of treatment of HCV-infected persons on development of HCC.
Purpose: To systematically review observational studies to determine the association between response to HCV therapy and development of HCC among persons at any stage of fibrosis and those with advanced liver disease.
Data sources: MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science, and the Database of Abstracts of Reviews and Effectiveness from inception through February 2012.
Study selection: English-language observational studies that compared therapy-derived sustained virologic response (SVR) with no response to therapy among HCV-infected persons, targeted an adult population, and had an average follow-up of at least 2 years.
Data extraction: Two investigators independently extracted data into uniform relative risk measures. The Grading of Recommendations Assessment, Development and Evaluation framework was used to determine the quality of the evidence.
Data synthesis: Thirty studies fulfilled the inclusion criteria, and 18 provided adjusted effect estimates that were used to calculate pooled relative risks. Among HCV-infected persons, SVR was associated with reduced risk for HCC (relative risk for all persons, 0.24 [95% CI, 0.18 to 0.31], moderate-quality evidence; advanced liver disease hazard ratio, 0.23 [CI, 0.16 to 0.35], moderate-quality evidence).
Limitation: In the meta-analyses, some variables could not be controlled for because of the observational design of the included studies.
Conclusion: Sustained virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated with reduced HCC. The evidence was determined to be of moderate quality.
Similar articles
-
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4. J Hepatol. 2017. PMID: 27818234
-
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19. Gastroenterology. 2017. PMID: 28642197
-
Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.J Clin Oncol. 2013 Apr 20;31(12):1514-21. doi: 10.1200/JCO.2012.44.6831. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509319
-
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?Am J Gastroenterol. 2003 Nov;98(11):2535-42. doi: 10.1111/j.1572-0241.2003.07678.x. Am J Gastroenterol. 2003. PMID: 14638360 Review.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
Cited by
-
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else?J Clin Med. 2024 Sep 14;13(18):5474. doi: 10.3390/jcm13185474. J Clin Med. 2024. PMID: 39336960 Free PMC article.
-
Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection.Cancers (Basel). 2024 Jul 18;16(14):2573. doi: 10.3390/cancers16142573. Cancers (Basel). 2024. PMID: 39061212 Free PMC article.
-
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.Hepatol Int. 2024 Oct;18(5):1459-1471. doi: 10.1007/s12072-024-10700-7. Epub 2024 Jul 5. Hepatol Int. 2024. PMID: 38965190
-
Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection.PLoS One. 2024 May 13;19(5):e0303265. doi: 10.1371/journal.pone.0303265. eCollection 2024. PLoS One. 2024. PMID: 38739590 Free PMC article.
-
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.Clin Mol Hepatol. 2024 Jul;30(3):326-344. doi: 10.3350/cmh.2024.0155. Epub 2024 Apr 26. Clin Mol Hepatol. 2024. PMID: 38665034 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical